Bulletin
Investor Alert

Moderna Inc.

NAS: MRNA

GO
/marketstate/country/us

After Hours

 --Quotes are delayed by 20 min

Jun 30, 2022, 7:59 p.m.

/zigman2/quotes/205619834/composite

$

141.77

Change

-1.08 -0.76%

Volume

Volume 87,213

Quotes are delayed by 20 min

/zigman2/quotes/205619834/composite

Today's close

$ 142.81

$ 142.85

Change

+0.04 +0.03%

Day low

Day high

$135.52

$147.35

Open

52 week low

52 week high

$115.61

$497.49

Open

Company Description

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therap...

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Valuation

P/E Current

5.04

P/E Ratio (with extraordinary items)

4.16

P/E Ratio (without extraordinary items)

8.97

Price to Sales Ratio

5.95

Price to Book Ratio

7.24

Price to Cash Flow Ratio

8.05

Enterprise Value to EBITDA

3.49

Enterprise Value to Sales

2.09

Efficiency

Total Asset Turnover

1.14

Liquidity

Current Ratio

1.76

Quick Ratio

1.60

Cash Ratio

1.18

Profitability

Gross Margin

84.53

Operating Margin

71.89

Pretax Margin

72.15

Net Margin

66.27

Return on Assets

75.78

Return on Equity

146.08

Return on Total Capital

148.24

Capital Structure

Total Debt to Total Assets

3.68

Officers and Executives

Name Age Officer Since Title
Mr. Stéphane Bancel 48 - President, Founding CEO & Director
Dr. Stephen Hoge 45 - SVP-Corporate Development & New Drug Concepts
Mr. David W. Meline 63 2022 Chief Financial Officer
Dr. Paul Burton 52 2021 Chief Medical Officer
Mr. Juan Andres 56 2017 Chief Technical Operations & Quality Officer

Insider Actions

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
06/16/2022 Stéphane Bancel
Chief Executive Officer; Director
10,000   Disposition at $124.29 per share. 1,242,900
06/16/2022 Stéphane Bancel
Chief Executive Officer; Director
11,195   Disposition at $120.69 per share. 1,351,124
06/16/2022 Stéphane Bancel
Chief Executive Officer; Director
15,005   Disposition at $119.85 per share. 1,798,349
06/16/2022 Stéphane Bancel
Chief Executive Officer; Director
13,800   Disposition at $119.16 per share. 1,644,408
06/16/2022 Stéphane Bancel
Chief Executive Officer; Director
40,000   Derivative/Non-derivative trans. at $0.99 per share. 39,600
06/15/2022 Stéphane Bancel
Chief Executive Officer; Director
2,800   Disposition at $130.63 per share. 365,764
06/15/2022 Stéphane Bancel
Chief Executive Officer; Director
9,206   Disposition at $129.87 per share. 1,195,583
06/15/2022 Stéphane Bancel
Chief Executive Officer; Director
9,451   Disposition at $128.84 per share. 1,217,666
06/15/2022 Stéphane Bancel
Chief Executive Officer; Director
6,225   Disposition at $127.88 per share. 796,053
06/15/2022 Stéphane Bancel
Chief Executive Officer; Director
4,279   Disposition at $126.75 per share. 542,363
06/15/2022 Stéphane Bancel
Chief Executive Officer; Director
5,659   Disposition at $125.87 per share. 712,298
06/15/2022 Stéphane Bancel
Chief Executive Officer; Director
2,380   Disposition at $124.63 per share. 296,619
06/15/2022 Stéphane Bancel
Chief Executive Officer; Director
40,000   Derivative/Non-derivative trans. at $0.99 per share. 39,600
06/13/2022 Stephen Hoge
President
10,000   Disposition at $123 per share. 1,230,000
06/13/2022 Stephen Hoge
President
5,000   Derivative/Non-derivative trans. at $10.9 per share. 54,500
06/13/2022 Stephen Hoge
President
5,000   Derivative/Non-derivative trans. at $10.9 per share. 54,500
06/09/2022 Stéphane Bancel
Chief Executive Officer; Director
10,000   Disposition at $148.07 per share. 1,480,700
06/09/2022 Stéphane Bancel
Chief Executive Officer; Director
1,605   Disposition at $141.79 per share. 227,572
06/09/2022 Stéphane Bancel
Chief Executive Officer; Director
2,871   Disposition at $140.85 per share. 404,380
06/09/2022 Stéphane Bancel
Chief Executive Officer; Director
1,483   Disposition at $139.61 per share. 207,041
06/09/2022 Stéphane Bancel
Chief Executive Officer; Director
2,155   Disposition at $138.58 per share. 298,639
06/09/2022 Stéphane Bancel
Chief Executive Officer; Director
10,458   Disposition at $137.58 per share. 1,438,811
06/09/2022 Stéphane Bancel
Chief Executive Officer; Director
12,629   Disposition at $136.71 per share. 1,726,510
06/09/2022 Stéphane Bancel
Chief Executive Officer; Director
7,517   Disposition at $135.6 per share. 1,019,305
06/09/2022 Stéphane Bancel
Chief Executive Officer; Director
1,282   Disposition at $134.68 per share. 172,659
06/09/2022 Stéphane Bancel
Chief Executive Officer; Director
40,000   Derivative/Non-derivative trans. at $0.99 per share. 39,600
06/08/2022 Stéphane Bancel
Chief Executive Officer; Director
6,700   Disposition at $151.39 per share. 1,014,313
06/08/2022 Stéphane Bancel
Chief Executive Officer; Director
3,328   Disposition at $150.75 per share. 501,696
06/08/2022 Stéphane Bancel
Chief Executive Officer; Director
15,972   Disposition at $149.94 per share. 2,394,841
06/08/2022 Stéphane Bancel
Chief Executive Officer; Director
14,000   Disposition at $148.19 per share. 2,074,660
06/08/2022 Juan Andres
See remarks
10,000   Disposition at $150 per share. 1,500,000
06/08/2022 Shannon Thyme Klinger
Chief Legal Officer
1,265   Disposition at $148.12 per share. 187,371
06/08/2022 Stéphane Bancel
Chief Executive Officer; Director
40,000   Derivative/Non-derivative trans. at $0.99 per share. 39,600
06/08/2022 Juan Andres
See remarks
629   Derivative/Non-derivative trans. at $14.22 per share. 8,944
06/08/2022 Juan Andres
See remarks
2,000   Derivative/Non-derivative trans. at $20.93 per share. 41,860
06/08/2022 Juan Andres
See remarks
2,000   Derivative/Non-derivative trans. at $20.93 per share. 41,860
06/08/2022 Juan Andres
See remarks
2,000   Derivative/Non-derivative trans. at $20.93 per share. 41,860
06/08/2022 Juan Andres
See remarks
2,000   Derivative/Non-derivative trans. at $20.93 per share. 41,860
06/08/2022 Juan Andres
See remarks
1,371   Derivative/Non-derivative trans. at $20.93 per share. 28,695
06/07/2022 Shannon Thyme Klinger
Chief Legal Officer
4,554   Derivative/Non-derivative trans. at $140 per share. 637,560
06/02/2022 Stéphane Bancel
Chief Executive Officer; Director
10,000   Disposition at $140 per share. 1,400,000
06/02/2022 Stéphane Bancel
Chief Executive Officer; Director
6,500   Disposition at $139.79 per share. 908,635
06/02/2022 Stéphane Bancel
Chief Executive Officer; Director
14,000   Disposition at $138.58 per share. 1,940,120
06/02/2022 Stéphane Bancel
Chief Executive Officer; Director
300   Disposition at $136.72 per share. 41,016
06/02/2022 Stéphane Bancel
Chief Executive Officer; Director
7,000   Disposition at $135.12 per share. 945,840
06/02/2022 Stéphane Bancel
Chief Executive Officer; Director
10,100   Disposition at $134.06 per share. 1,354,006
06/02/2022 Stéphane Bancel
Chief Executive Officer; Director
900   Disposition at $132.68 per share. 119,412
06/02/2022 Stéphane Bancel
Chief Executive Officer; Director
1,200   Disposition at $131.56 per share. 157,872
06/02/2022 Stéphane Bancel
Chief Executive Officer; Director
40,000   Derivative/Non-derivative trans. at $0.99 per share. 39,600
06/01/2022 Stéphane Bancel
Chief Executive Officer; Director
400   Disposition at $148.44 per share. 59,376
06/01/2022 Stéphane Bancel
Chief Executive Officer; Director
800   Disposition at $147.46 per share. 117,968
06/01/2022 Stéphane Bancel
Chief Executive Officer; Director
1,063   Disposition at $146.65 per share. 155,888
06/01/2022 Stéphane Bancel
Chief Executive Officer; Director
4,137   Disposition at $145.62 per share. 602,429
06/01/2022 Stéphane Bancel
Chief Executive Officer; Director
5,329   Disposition at $144.33 per share. 769,134
06/01/2022 Stéphane Bancel
Chief Executive Officer; Director
12,049   Disposition at $143.58 per share. 1,729,995
06/01/2022 Stéphane Bancel
Chief Executive Officer; Director
13,056   Disposition at $142.51 per share. 1,860,610
06/01/2022 Stéphane Bancel
Chief Executive Officer; Director
3,166   Disposition at $141.67 per share. 448,527
06/01/2022 Stéphane Bancel
Chief Executive Officer; Director
40,000   Derivative/Non-derivative trans. at $0.99 per share. 39,600
05/31/2022 Stephen Hoge
President
7,431   Disposition at $144.97 per share. 1,077,272
05/31/2022 Stephen Hoge
President
999   Disposition at $145.4 per share. 145,254
05/31/2022 Juan Andres
See remarks
749   Disposition at $145.4 per share. 108,904
05/31/2022 Stephen Hoge
President
7,431   Derivative/Non-derivative trans. at $0.99 per share. 7,356
05/27/2022 Stephen Hoge
President
2,410   Derivative/Non-derivative trans. at $135.8 per share. 327,278
05/27/2022 Juan Andres
See remarks
1,807   Derivative/Non-derivative trans. at $135.8 per share. 245,390
/news/latest/company/us/mrna

MarketWatch News on MRNA

  1. Moderna Inc. stock outperforms competitors on strong trading day

    4:31 p.m. Today

    - MarketWatch Automation

  2. FDA Asks for Fall Boosters to Target BA.5

    1:45 p.m. Today

    - Josh Nathan-Kazis

  3. FDA Asks Vaccine Makers for Boosters to Target BA.5

    12:02 p.m. Today

    - Josh Nathan-Kazis

  4. FDA says COVID-19 boosters should be updated to combat two omicron subvariants

    10:49 a.m. Today

    - Jaimy Lee

  5. Pfizer Raises Covid Vaccine Price 27%. What It Means for the Stock.

    9:04 a.m. Today

    - Josh Nathan-Kazis

  6. Moderna Inc. stock rises Wednesday, outperforms market

    4:31 p.m. June 29, 2022

    - MarketWatch Automation

  7. FDA Advisers Sign Off on Omicron Booster

    8:23 a.m. June 29, 2022

    - Josh Nathan-Kazis

  8. Moderna Inc. stock outperforms market despite losses on the day

    4:31 p.m. June 28, 2022

    - MarketWatch Automation

  9. J&J does not plan to update its COVID-19 vaccine

    1:33 p.m. June 28, 2022

    - Jaimy Lee

  10. Moderna Inc. stock outperforms market on strong trading day

    4:31 p.m. June 27, 2022

    - MarketWatch Automation

  11. FDA Panel Will Weigh In on Covid Boosters for This Fall

    3:00 a.m. June 27, 2022

    - Josh Nathan-Kazis

  12. COVID vaccines for kids under 5 — what parents need to know

    4:09 p.m. June 25, 2022

    - Nicole Lyn Pesce

  13. Loading more headlines...
/news/nonmarketwatch/company/us/mrna

Other News on MRNA

  1. FDA Directs Drug Makers on Fall Covid-19 Boosters

    3:47 p.m. Today

    - Peter Loftus

  2. Could This Send Moderna's Stock Soaring Back to $400?

    11:45 a.m. Today

    - Motley Fool

  3. Is Pfizer Stock a Buy Now?

    11:30 a.m. Today

    - Motley Fool

  4. 3 Things About Moderna That Smart Investors Know

    10:45 a.m. Today

    - Motley Fool

  5. FDA requests manufacturers to update vaccines for latest Omicron subvariants

    10:41 a.m. Today

    - Seeking Alpha

  6. Greenblatt's Magic Formula For Beating The Market

    10:41 a.m. Today

    - Seeking Alpha

  7. Pfizer (PFE) Inks Deal With US Government for COVID Jab Supply

    10:03 a.m. Today

    - Zacks.com

  8. Healthcare Sector Stock Performance Continues To Improve

    7:15 a.m. Today

    - Seeking Alpha

  9. U.S. Agrees to Pay $3.2 Billion for More Pfizer Covid Vaccines

    6:38 p.m. June 29, 2022

    - Andrew Restuccia

  10. 2 Dividend Stocks With Huge Passive Income Potential

    5:41 a.m. June 29, 2022

    - Motley Fool

  11. FDA targets updated COVID-19 vaccines for adults by October

    12:40 p.m. June 28, 2022

    - Seeking Alpha

  12. The 3 Smartest Real Estate Stocks to Buy Right Now

    7:00 a.m. June 28, 2022

    - Motley Fool

  13. Moderna (MRNA) Gains As Market Dips: What You Should Know

    5:50 p.m. June 27, 2022

    - Zacks.com

  14. Loading more headlines...

At a Glance

Moderna, Inc.

200 Technology Square

Cambridge, Massachusetts 02139

Phone

1 6177146500

Industry

-

Sector

-

Fiscal Year-end

12/2022

Revenue

$18.41B

Net Income

$12.20B

Employees

2,700

/news/pressrelease/company/us/mrna

Press Releases on MRNA

  1. Moderna Inc. Common Stock MRNA Trading Advice

    2:54 a.m. June 28, 2022

    - Stock Traders Daily

  2. Nasdaq 100 Movers: MRNA, PYPL

    10:22 a.m. June 24, 2022

    - MarketNewsVideo.com

  3. S&P 500 Movers: UNH, NCLH

    10:18 a.m. June 24, 2022

    - MarketNewsVideo.com

  4. Best Health Care Stocks To Buy Now? 3 To Watch

    9:32 a.m. June 20, 2022

    - StockMarket.com

  5. Moderna Inc. Common Stock MRNA Investment Analysis

    8:01 a.m. June 18, 2022

    - Stock Traders Daily

  6. Nasdaq 100 Movers: NTES, KDP

    10:30 a.m. June 16, 2022

    - MarketNewsVideo.com

  7. Nasdaq 100 Movers: NTES, KDP

    10:29 a.m. June 16, 2022

    - MarketNewsVideo.com

  8. Top Stock Market News For Today June 15, 2022

    6:28 a.m. June 15, 2022

    - StockMarket.com

  9. Top Biotech Stocks To Invest In Today? 3 To Watch This Week

    8:57 a.m. June 12, 2022

    - StockMarket.com

  10. S&P 500 Movers: MO, ETSY

    10:29 a.m. June 8, 2022

    - MarketNewsVideo.com

  11. Novavax Shoots Higher on FDA OK for COVID Vaccine

    9:42 a.m. June 8, 2022

    - Baystreet.ca

  12. Loading more headlines...
Link to MarketWatch's Slice.